WebOct 28, 2024 · Redeye: Adding an indication We had the opportunity to dig deeper in to the commercial potential for AP1189 in nephrotic syndrome. As a result, we raise our base case valuation to SEK 17 per share. Documents Research report – Redeye: Adding an indication October 28, 2024 English WebWith RedEye DMS easily find the latest asset information, empowering your teams to be safer and more efficient. Workflows and approvals are streamlined. Connect your …
Redeye: Adding an indication – SynAct Pharma
WebRedEye’s advanced technology enables marketers to reduce their tech stack by providing all the tools they need to build and grow the sophistication of their marketing campaigns. … WebOct 1, 2024 · The SynAct team have successfully taken compounds through Phase I and II together before and has skin in the game, sitting on more than 30% of the shares. While nearer-term upside is limited by the company’s need for new capital this year, our risk-adjusted DCF model suggests a base valuation of SEK 13 per share, which comparison … crossbow laser boresighter bolt
SynAct Pharma Announces Positive Interim Phase 2 Data of …
WebSynAct Pharma AB is a pharmaceutical company focused on resolution of inflammation through melanocortin system activation. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help … WebSynAct Pharma AB develops drugs for acute deterioration in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriatic arthritis - a form of acute joint disorder that affects approximately 30 percent of patients suffering from psoriasis. Preclinical studies show that AP1189 has a WebSep 1, 2024 · SynAct Pharma AB hereby informs that the company has terminated the agreement with Redeye relating to the coverage of the company. For further information, … crossbow laser